Basic Science Clinical
Vascular Headache Epilepsy Immunology Movement Neuromuscular Dementia Other Topics Neurosurgery
Clinical
Dementia
9 notes available
1 Last Minute Review 2 Alzheimer Disease 3 Frontotemporal Dementia 4 Lewy Body & Parkinson Dementia 5 Vascular Cognitive Impairment 6 Rapidly Progressive Dementias 7 Reversible & Secondary Dementias 8 Mild Cognitive Impairment & Dementia Workup 9 Behavioral & Psychiatric Features
Clinical › Dementia

Lewy Body & Parkinson Dementia

Dementia with Lewy Bodies & Parkinson Disease Dementia

What You'll Learn

  • DLB core features: fluctuating cognition, recurrent well-formed visual hallucinations, REM sleep behavior disorder (RBD), spontaneous parkinsonism
  • 1-year rule: dementia within 1 year of parkinsonism = DLB; dementia ≥1 year after established parkinsonism = PDD — same α-synuclein Lewy body pathology on a spectrum
  • Neuroleptic sensitivity: even atypical antipsychotics can cause severe/fatal reactions; if absolutely needed → low-dose quetiapine or clozapine (per 2017 DLB consensus); pimavanserin is sometimes used off-label in DLB but is FDA-approved only for PD psychosis
  • Indicative biomarkers: reduced dopamine transporter uptake (DaTscan), abnormal 123I-MIBG cardiac scintigraphy, PSG-confirmed RBD without atonia
  • Cognitive profile: attention, executive function, and visuospatial domains disproportionately impaired early; memory relatively preserved (vs. AD)
  • Treatment: rivastigmine (strongest evidence among cholinesterase inhibitors); for RBD in DLB/PDD, secure the sleep environment and use a guideline-supported agent — AASM 2023 conditionally recommends immediate-release melatonin, clonazepam, and rivastigmine; IR melatonin is often preferred initially in dementia for safety, with clonazepam reserved (caution: falls, delirium, OSA); cautious carbidopa-levodopa for motor symptoms
  • Imaging: relative preservation of medial temporal lobe/hippocampus (vs. AD); occipital hypometabolism on FDG-PET; "cingulate island sign"
HighYield Pearls
  • 4 core clinical features (McKeith 2017): fluctuating cognition, recurrent well-formed visual hallucinations, RBD, spontaneous parkinsonism — ≥2 features = probable DLB (or 1 core + ≥1 indicative biomarker)
  • 1-year rule: dementia onset ≤1 yr of parkinsonism = DLB; dementia >1 yr after established parkinsonism = PDD — same underlying α-synuclein Lewy body pathology
  • Neuroleptic sensitivity is a hallmark: AVOID haloperidol/typical antipsychotics (severe rigidity, NMS-like reaction, death) — use low-dose quetiapine cautiously; pimavanserin (5HT2A inverse agonist, no D2 block) off-label for psychosis
  • Indicative biomarkers (can upgrade certainty): DaTscan with reduced striatal dopamine uptake, PSG-confirmed REM sleep without atonia, reduced 123I-MIBG cardiac uptake
  • Supportive biomarkers: relative MTL preservation (vs. AD), posterior hypometabolism with cingulate island sign on FDG-PET, posterior slow-wave EEG with pre-α/θ fluctuations
  • DLB vs. AD: visual hallucinations + fluctuations + RBD + DaTscan abnormal (normal in AD) + MTL preserved — AD co-pathology common
  • RBD predicts synucleinopathy: ~75–80% of isolated RBD converts to DLB/PD/MSA over 12–14 yr — counsel on future risk
  • Treatment pearls: rivastigmine (strongest evidence) > donepezil for cognition; for RBD secondary to DLB/PDD, secure the sleep environment — AASM 2023 conditionally recommends IR melatonin, clonazepam, and rivastigmine; IR melatonin is often preferred initially in dementia for safety (vs. clonazepam, which carries falls / delirium / OSA risk); cautious levodopa (may worsen hallucinations); AVOID anticholinergics, antihistamines, benzodiazepines (as a class)
🔍 Quick ReferenceClinical · Imaging · Pathology / treatment
Clinical phenotype
  • Fluctuating cognition with episodes of staring/unresponsiveness then alert → DLB core feature
  • Recurrent well-formed visual hallucinations of people, animals, or children → DLB (often with preserved insight early)
  • Dream enactment behavior / RBD preceding dementia by years to decades → prodromal α-synucleinopathy (DLB/PD/MSA)
  • Severe extrapyramidal reaction / NMS-like response to haloperidol or typical antipsychotic → neuroleptic sensitivity in DLB
  • Capgras syndrome (familiar people are imposters) → DLB-associated delusional misidentification
  • Unexplained syncope, recurrent falls, orthostatic hypotension, hyposmia → DLB supportive features
  • Marked confusion/worsening with diphenhydramine or anticholinergic → DLB sensitivity
Imaging signs
  • Reduced striatal dopamine transporter uptake on DaTscan → DLB (or PD/MSA/PSP) — normal in AD
  • Cingulate island sign on FDG-PET (posterior cingulate spared, precuneus/lateral parietal hypometabolic) → DLB
  • Occipital hypometabolism on FDG-PET → DLB (distinguishes from AD)
  • Relative medial temporal lobe / hippocampal preservation on MRI → DLB (vs. prominent MTL atrophy in AD)
  • Reduced 123I-MIBG cardiac scintigraphy (postganglionic sympathetic denervation) → DLB/PD — normal in MSA
  • Posterior slow-wave EEG with pre-α/θ fluctuations → DLB supportive biomarker
Pathology / treatment pearls
  • Brainstem and cortical α-synuclein Lewy bodies + Lewy neurites → DLB / PDD pathology (concomitant AD pathology common)
  • Rivastigmine → strongest evidence cholinesterase inhibitor for DLB cognition and hallucinations
  • Pimavanserin (5HT2A inverse agonist, no D2 block) → off-label DLB psychosis; FDA-approved for PD psychosis
  • Low-dose quetiapine or clozapine → cautious antipsychotic choice if absolutely needed
  • Immediate-release melatonin → AASM 2023 conditionally recommended for RBD; often preferred initially in dementia for safety (vs. clonazepam, which is also guideline-supported but carries falls / delirium / OSA risk)
  • Cautious carbidopa-levodopa → parkinsonism in DLB (may worsen hallucinations/psychosis)
  • Avoid anticholinergics, antihistamines (diphenhydramine), benzodiazepines → worsen confusion in DLB
  • DBS → NOT indicated in DLB/PDD (cognitive impairment is a contraindication)
DLB Diagnostic Criteria (McKeith 2017)

Essential Feature (Required)

  • Dementia — progressive cognitive decline of sufficient magnitude to interfere with social/occupational function; prominent or persistent memory impairment may not occur early but usually evident with progression. Required for any DLB diagnosis.

Core Clinical Features

  • Fluctuating cognition — pronounced variations in attention and alertness; may mimic delirium; spontaneous "good days and bad days"
  • Recurrent visual hallucinations — well-formed, detailed (people, animals, children); often have insight early in course
  • REM sleep behavior disorder (RBD) — dream enactment behavior; loss of normal REM atonia; may precede cognitive decline by decades
  • Spontaneous parkinsonism — bradykinesia, rigidity, rest tremor; NOT drug-induced; often symmetric or mild early on

Diagnostic Certainty

Diagnosis Criteria
Probable DLB≥2 core features; OR 1 core feature + ≥1 indicative biomarker
Possible DLB1 core feature without indicative biomarker; OR ≥1 indicative biomarker alone (no core features)

Indicative Biomarkers

Biomarker What It Shows Board-Relevant Details
DaTscan (Ioflupane SPECT)Reduced dopamine transporter uptake in basal gangliaAbnormal in DLB, PD, MSA, PSP; normal in AD — key differentiator
123I-MIBG cardiac scintigraphyReduced cardiac sympathetic innervationAbnormal in DLB and PD (cardiac sympathetic denervation); normal in AD, MSA
PSG-confirmed RBDREM sleep without atonia on polysomnographyRBD converts to α-synucleinopathy (DLB/PD/MSA): Postuma 2019 multicenter cohort showed ~74% phenoconversion at 12 years; long-term cumulative rates ~75–80%

Supportive Clinical Features

  • Severe neuroleptic sensitivity — exaggerated extrapyramidal response to antipsychotics; can be fatal
  • Postural instability and repeated falls
  • Syncope or other transient episodes of unresponsiveness
  • Severe autonomic dysfunction (orthostatic hypotension, urinary incontinence, constipation)
  • Hypersomnia
  • Hyposmia (reduced sense of smell)
  • Systematized delusions (often paranoid/persecutory)
  • Hallucinations in other modalities (auditory, tactile)
  • Apathy, anxiety, depression

Supportive Biomarkers

  • Relative preservation of medial temporal lobe on CT/MRI (vs. prominent hippocampal atrophy in AD)
  • Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity
  • Prominent posterior slow-wave activity on EEG with periodic fluctuations in the pre-alpha/theta range
  • Insular thinning on MRI
💎 Board Pearl
  • Probable DLB requires ≥2 core features OR 1 core + 1 indicative biomarker — biomarkers can "upgrade" a single core feature to probable
  • DLB should NOT be diagnosed if parkinsonism is the only core feature and DaTscan is the only biomarker (both reflect same dopaminergic loss)
  • RBD is the most specific predictor of future α-synucleinopathy — if present with cognitive decline, DLB is the leading differential
  • Supportive biomarkers (MRI MTL preservation, occipital hypometabolism on FDG-PET, EEG posterior slow waves) are consistent with DLB but do NOT by themselves allow a Probable DLB diagnosis — only INDICATIVE biomarkers (DaTscan, MIBG, PSG-confirmed RBD) can upgrade certainty to Probable DLB
🔒

Continue reading — sign in

The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.

Sign in Create free account